BioMérieux BIOFIRE Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Becomes First COVID-19 Diagnostic Test to Obtain De Novo FDA Authorization
|
By HospiMedica International staff writers Posted on 19 Mar 2021 |
|
Image: BIOFIRE RP2.1 Panel (Photo courtesy of BioMérieux)
BioMérieux (Marcy-l'Étoile, France) has received US Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE RP2.1 Panel, making it the first SARS-CoV-2 diagnostic test of any kind to be granted De Novo status by US FDA.
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Hemostatic Agent
HEMOBLAST Bellows
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Critical Care
view channel
CPR Guidelines Updated for Pediatric and Neonatal Emergency Care and Resuscitation
Cardiac arrest in infants and children remains a leading cause of pediatric emergencies, with more than 7,000 out-of-hospital and 20,000 in-hospital cardiac arrests occurring annually in the United States.... Read more
Ingestible Capsule Monitors Intestinal Inflammation
Acute mesenteric ischemia—a life-threatening condition caused by blocked blood flow to the intestines—remains difficult to diagnose early because its symptoms often mimic common digestive problems.... Read more
Wireless Implantable Sensor Enables Continuous Endoleak Monitoring
Endovascular aneurysm repair (EVAR) is a life-saving, minimally invasive treatment for abdominal aortic aneurysms—balloon-like bulges in the aorta that can rupture with fatal consequences.... Read more
Wearable Patch for Early Skin Cancer Detection to Reduce Unnecessary Biopsies
Skin cancer remains one of the most dangerous and common cancers worldwide, with early detection crucial for improving survival rates. Traditional diagnostic methods—visual inspections, imaging, and biopsies—can... Read moreSurgical Techniques
view channel
Major Study Examines Endoscopies that Fail to Detect Esophageal Cancer
Barrett’s esophagus—the only known precancerous condition for esophageal adenocarcinoma—develops when chronic acid reflux damages the esophageal lining. Endoscopies are typically used to monitor such patients... Read more
Robotic Assistant Delivers Ultra-Precision Injections with Rapid Setup Times
Age-related macular degeneration (AMD) is a leading cause of blindness worldwide, affecting nearly 200 million people, a figure expected to rise to 280 million by 2040. Current treatment involves doctors... Read more
Patient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies
Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
B. Braun Acquires Digital Microsurgery Company True Digital Surgery
The high-end microsurgery market in neurosurgery, spine, and ENT is undergoing a significant transformation. Traditional analog microscopes are giving way to digital exoscopes, which provide improved visualization,... Read more
CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is scheduled to be held from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou.... Read more